October 26, 2016 SBI Pharmaceuticals Co., Ltd.

Exclusive License Agreement Concluded with Neopharma on the Therapeutic Drugs for Diabetes and Malaria Infection

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; "SBI Pharmaceuticals"), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid ("5-ALA")*1, hereby announces that SBI Pharmaceuticals has concluded the exclusive license agreement with Neopharma LLC. (Head office: Abu Dhabi, U.A.E; Executive Vice Chairman & Managing Director: B. R. Shetty, Ph.D.; "Neopharma" *2) on the therapeutic drugs for diabetes and malaria infection.

SBI Pharmaceuticals will, under this agreement, grant to Neopharma the worldwide right and license of the patents and know-how on the treatment of diabetes and malaria infection using 5-ALA, and receive, in consideration for the grant, an upfront payment and the milestones by the progress of the development.

The efficacies of 5-ALA have already been confirmed in cultured cells and animal models in the development for the therapeutic drugs to treat diabetes and malaria infection. The Phase I study conducted in the United Kingdom was completed and the safety in healthy subject has been confirmed. Neopharma will from now on conduct clinical trials (Phase II/III) with National Institute of Malaria Research in India on malaria infection and other foreign medical institutions on diabetes.

SBI Pharmaceuticals will continue to pursue various potential applications of 5-ALA, and focus on research and development to provide pharmaceuticals that satisfy the unmet medical needs of as many people as possible around the world.

(*1) 5-aminolevulinic acid (5-ALA)

An amino acid created in mitochondria. It is an important substance that serves as a functional molecule

related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

(*2): Neopharma

A corporation established in U.A.E. in 2003 to manufacture and market pharmaceuticals; such as, Neopharma brand generics of anti-infectives, analgesics, antipyretics and anti-inflammatory drugs, drugs for diabetes, cardiovascular drugs, respiratory medicines, gastrointestinal drugs and vitamins. The

corporation has deep connections with the Royal family, and its corporate group holds such a promising enterprise as NMC Health PLC (Listed in London Stock Exchange), currently running in Abu Dhabi the largest private hospital, where over 3 million patients visit per year.

*******************************************

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095

SBI Holdings Inc. published this content on 26 October 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 October 2016 07:56:06 UTC.

Original documenthttp://www.sbigroup.co.jp/english/news/pdf/2016/1026_a_en.pdf

Public permalinkhttp://www.publicnow.com/view/97D71BC0E5199F97DF374CB75287258024F20A33